Loading...

DMTK - DermTech, Inc.

Analyst Reiterated Signal for 06-14-2022
Analyst Reiterated/Price Target Changed: DMTK rating Buy by BTIG Research
Price Target: $38>>19



Stock Signal Information


Signal

Analyst Reiterated Stock
Report Date: 06-14-2022
Symbol: DMTK - DermTech, Inc.
Sector: Healthcare
Industry: Diagnostics & Research
Analyst Reiterated/Price Target Changed: DMTK rating Buy by BTIG Research
Price Target: $38>>19

  DMTK Technical Chart

Company Contact

DermTech, Inc. (DMTK)
11099 N Torrey Pines Rd Ste 100
La Jolla, CALIFORNIA 92037
Phone: 18584504222
Website: https://www.dermtech.com
CEO: Dr. John D. Dobak


Company Profile

DermTech, Inc. is a genomics company in dermatology, which engages in the development and sale of products for the diagnosis and treatment of skin diseases. The company is headquartered in La Jolla, California. The firm develops products that facilitate the early detection of skin cancers, assess inflammatory diseases and customize drug treatments. The firm provides Adhesive Skin Collection Kit, which is designed to collect stratum corneum tissues of the skin from all locations of the body, with the exception of mucosals surfaces, palmar and plantar surfaces, and areas with excessive non-vellus hair. The company provides Pigmented Lesion Assay (PLA), which assesses pigmented skin lesions, moles or dark skin spots for melanoma. The company offers Nevome, which is the test to non-invasively identify pigmented lesions by analyzing known deoxyribonucleic acid (DNA) mutation risk factors for melanoma. The firm is also engaged in developing gene expression assays to identify cytokine inflammatory profiles that assist clinicians in guiding therapy. The company also offers ResponseTNF product and CytokineEx 17 product.